This inventor holds 8 USPTO granted patents. Top assignees: Dojindo Laboratories, Bloom Technology, Inc., Daiichi Pure Chemicals Co., Ltd.. Active years: 1993-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Mashiki-machi, JP (1996)
- Kamimashiki-gun, JP (1999)
- Kumamoto, JP (1993 - 2024)
Company Filing History:
4 out of 10 
2 out of 4 
1 out of 59 
Years Active: 1993-2025
Title: Kazumi Sasamoto: Innovator in Monoclonal Antibody Research
Introduction
Kazumi Sasamoto is a notable inventor based in Kumamoto, Japan. He has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. With a total of 8 patents, his work has the potential to impact medical diagnostics and treatment.
Latest Patents
Sasamoto's latest patents focus on an antibody against advanced glycation end products (AGEs). The present invention is directed to providing a monoclonal antibody that exhibits high selectivity and affinity for AGEs, especially those derived from glyceraldehyde or glycolaldehyde. Additionally, the invention includes an analysis method utilizing this antibody. Another objective of the invention is to provide methods for diagnosing, treating, and preventing diseases using the monoclonal antibody.
Career Highlights
Throughout his career, Kazumi Sasamoto has worked with reputable companies such as Dojindo Laboratories and Bloom Technology, Inc. His experience in these organizations has allowed him to refine his skills and contribute to groundbreaking research in his field.
Collaborations
Sasamoto has collaborated with several professionals, including Masanobu Shiga and Munetaka Ishiyama. These partnerships have fostered innovation and have been instrumental in advancing his research endeavors.
Conclusion
Kazumi Sasamoto's work in monoclonal antibody research exemplifies the importance of innovation in biotechnology. His contributions have the potential to lead to significant advancements in medical science and patient care.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile